Skip to content
Fouad – Managing Massive Hemoptysis episode artwork

Jan 9, 2023 54 min

Fouad – Managing Massive Hemoptysis

from Maryland CC Project

Dr. Jan Fouad is a recent graduate of the Pulmonary, Critical Care, and Sleep Medicine Fellowship at the Yale School of Medicine and is currently an Interventional Pulmonology Fellow at the University of Maryland. He presents a lecture entitled "Managing Massive Hemoptysis" as part of the DC5 lecture series.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Fouad – Managing Massive Hemoptysis

0:00 54:14
of matches

Transcript Auto-generated, may contain errors

all right so welcome to dc5 curriculum for today thanks everyone for joining us um so today's speaker is going to be jan foad so he is one of our interventional pulmonary fellows here at university of maryland he is a recent graduate of yale pulmonary and critical care and sleep medicine and joined us here i guess in july of this year jan's basically crushing it here at university of maryland and he's an absolute pleasure to work with um a lot of our ip team is actually at chest and um and has also been called into emergent cases today in the operating room so in addition to um jan being a superstar fellow here he's agreed to step in last minute to give this talk um obviously there's no one more qualified to do so given this is the bread and butter of what he manages um but a special thanks to him for being willing to step in kind of at the last minute so jan without further ado i will turn it over to you Thank you for the kind introduction, Dr. Levine. As she mentioned, my name is Jan Buat. I'm the Interventional Pulmonology Fellow at the University of Maryland. So you'll have to forgive me both, and I'm not acquainted with this office nor this PowerPoint. So if there's a little bit of deliberate movement, please forgive me. But otherwise, hopefully we should be able to get through this together and get some good learning out of it. I think Komopsis is really good because we do see it. It's always a controversial topic in how we define it, how we manage it. The people that are involved are not involved in the case, and usually the first steps, as challenging and anxiety-provoking as it is, really it's if you proceed with a thoughtful, algorithmic approach to it, it should be.

So fairly straightforward in at least those first steps and how you get through it. So no disclosures of my own. I don't make any money, unfortunately. So the point of this talk really is, one, to define what we think about when we say massive homopsis, discuss the etiologies of massive homopsis, review the management, first how to stabilize the patient, discuss the therapies, whether that be medical, procedural, surgical, et cetera, and then go through a case or two about, you know, the approaches that have been taken and whether anything you guys had any thoughts about what could be missed or what should be done in certain specific instances. So, definitions. I think you guys have probably learned at this point that, you know, hemophysis in general, obviously, is a spitting of blood. Very often, the call for hemophysis is confounded by other areas of bleeding, right? We get called for hemophysis. It ends up being a nasal bleed. We get called for hemophysis that's actually hematemesis. And so, as silly as it sounds to define hemophysis in and of itself, it is really important to get a good history because, realistically, as many times as we do get true hemophysis in these presentations, we often get these obscuring pictures where someone might have had vomiting and then coughing of blood, and it's hard to differentiate, really, the localizing source, right?

As far as defining submassive or non-massive amoptosis versus massive amoptosis, you know, there have always been volume-based definitions that have existed clinically, whether that be predicated on per unit time or some volume. You know, people have defined things like 100 milliliters in six hours, 600 milliliters in 24 hours. I've seen 500 milliliters in 24 hours, multiple episodes in kind of the same 24-hour period. These definitions have fallen by the wayside for multiple reasons. The first being, truly, it is difficult to characterize and quantify hemoptysis. Very rarely is a patient completely coughing all of their blood into a cancer like you see here, right? They're coughing into a napkin, into a toilet, into a sink, and you don't really have a good quantifying approach to it. And the other thing is it's very difficult to trust the assessment of a patient, right? Is this pure blood that's being expectorated? Is this blood that's coming and it's sputum with blood within it? So for these reasons and others, it's important to kind of standardize your approach to what you consider massive hemoptysis versus non-massive hemoptysis.

So a better term is really one which causes some kind of phonically significant event, right? Whether that be airway obstruction, hypoxemia, need for mechanical ventilation, or hemodynamic instability. It is rarely really the fourth one that people present with, right? When someone has such significant hemoptysis that they're hemodynamically unstable, then really the ship has sailed in many ways. And oftentimes when we're talking about the cause of death of mass hemoptysis, it is not that they have bled out, but rather that they've asphyxiated. And depending on how sick or well the person is, just 50 milliliters of blood in the wrong place in someone with chronic respiratory failure can be enough to cause asphyxiation.

I think really the terminology is predicated on whether this is life-threatening versus a non-life-threatening homopsis rather than trying to define it by volume per unit time, as this has proven difficult, and clinically the significance of it is predicated from person to person. The other thing to talk about is really, you know, what the rate of bleeding is and is the patient able to protect their airway, right? So I think there's some reaction for most people as they hear him off, as we say intubate. And I think it's important to take a step back and ask ourselves, what is our goal in intubating a patient? You know, if someone's having a high rate of bleeding, altered inability to protect their airway, and there's an intervention that needs to be done, certainly an intubation is very reasonable. If someone expectorates a little bit of blood, is otherwise on room air, has a strong cough reflex, is young and healthy without comorbidities, perhaps you're taking away their best ability to protect their own airway, which is a cough reflex, right?

So it's not necessarily as simple as every hemoptysis should be intubated or every hemoptysis patient needs, you know, advanced procedures, which we'll talk about, but rather understanding kind of the prototype patient that you might be rushing to intubate. Again, altered, inability to protect airway, high rate of bleeding, poor cop reflex, multiple comorbidities, hemodynamic instability. Those would all kind of rush me towards an intubation process rather than just saying all cause hemoptysis straight to intubate. As far as the anatomy is concerned, we know that the bronchial artery bleeding is 90% of massive hemopsis, and usually pulmonary artery bleeding is only about 10%. Most of this is predicated on the blood pressure that is associated with these systems. The bronchial artery system is a systemic system that's coming off an aortic root, and thus we're talking about kind of, you know, systolic blood pressures in the hundreds of these vessels, whereas the pulmonary arteries, unless someone has, you know, severe pulmonary hypertension, a systolic blood pressure should be closer to 15 or 20 millimeters of mercury.

And such low-pressure systems with a high capacitance should allow for relatively low incidence of hemoptysis relative to the bronchial arteries. Now, as far as ideologies are concerned, I mean, we could spend a whole day talking about each one of these. There is every system and systemic processes cause hemoptysis. Of course, people with congenital heart disease and congestive heart failure by virtue of caperitis can develop hemoptysis or kind of frothy pink sputum that may appear to be hemoptysis. There's, you know, multitude of iatrogenic causes, of course.

Any sort of pistolization that might happen post-procedurally. Of course, any kind of catheterization that can cause a vascular to rupture. Administration of thrombolytic therapy, trans thoracic needle biopsies, all these things in tandem. one of the most common causes that we see. You know, fungal infections, TB, non-tuberculous mycobacterium can certainly be a cause. There are a host of anticoagulant and non-anticoagulant-based medications that can do it. And as we're seeing more and more novel therapies for cancer treatments, many of these are being seen to be associated with hemophysis as well. Of course, drugs like cocaine can do with blast injuries. There's multiple cryptogenic or traumatic-based diseases. We'll very often see it in bronchiectasis as there is kind of an erosion of a dilated airway next to a vascular system, very common ones that we see kind of opening up and closing over and over.

And then, you know, one of the most kind of METSOL-based quizzes that you'll get is things like diffuse alveolar hemorrhage from, you know, granulomatosis, polyamchitis, good pastures, et cetera, et cetera. Now, malignancy certainly is a cause. If you have massive hemophysis, more often than not, that type of hemophysis will come from a central malignancy rather than a portal malignancy. All comers, when you have non-massive hemophysis associated with malignancy, something like 7%, 10% of all lung cancers will have a presentation associated with hemophysis. Very often, this is non-massive rather than massive.

All comers who have any type of cancer altogether will develop hemoptysis somewhere like 20% of the time in their lifetime. And so this is not an insignificant amount of time. It's something to anticipate. Do develop hemoptysis as a product of metastatic disease or malignant disease. Generally, the vast majority of them, four out of every five, will have what's described as bleeding cough and then stabilize out. And weeks later, they'll come back and have kind of a significant hemoptysis episode. So it's always something to look for. And if evaluated early, it should be kind of intervened upon because the likelihood of them developing massive hemoptysis or significant hemoptysis is quite high later. As I mentioned, bronchiectasis infection is a very common.

etiologic cause that we talk about. So things like bronchitis, mycobacteria, fungal infections, lung abscesses, all of these things are really highly concerning. And the images you see in these CT scans here should really be burned in your brain. Anytime someone develops hemopsis and you get a CT scan where you're seeing things like fungal balls, these crescent signs, you see things like these large cavitating lesions, there's a high likelihood of kind of eroding into a peripheral airway and then therefore eroding into kind of a subset of blood vasculature thereafter. So when you have hemopsis and you see an image like this, it's really important to ask yourself, you know, is this a high-risk patient and what's the likelihood of them bleeding again?

particularly even with intervention, things like bronchiectasis, mycobacterium, and fungal infections, there's a high risk of re-bleeding relative to other causes of hemoptysis. So it's really a thing to think about. So localization, right? So once you have a patient that's developing hemoptysis and you're kind of staring them in the face, you have to ask yourself first, do I know what side it's coming from? And then can I even localize it better than that? This is important both for how you manage them initially and how you ultimately manage them from a kind of finality standpoint. And so we know chest actors are notoriously poor, showing us a source of hemoptysis, right?

Maybe at most 50% of the time a chest x-ray can localize beyond seeing this nonspecific ground glass opacity or kind of consolidated processes from dependent aspiration of blood. Traditional CT scans tend to be better around 70%. Bronchoscopies similarly can lateralize more often than not. However, their use in tandem is quite useful, and so you can get localization closer to 80-85% of the time. The reason really using them in tandem is one you can localize both from an endobronchial perspective but also from a vascular perspective, and that's important in terms of any therapeutics you may be able to offer.

Sometimes you can't localize it, and that might be because the patient has stopped bleeding altogether, and so by the time you get to things like a bronchoscopy or a CT angiogram, there's just no bleeding coming out, and you might not be able to identify a source. And sometimes the opposite is unfortunately true, where they are bleeding so significantly from their airway that it's hard to visualize anything, even up to being in kind of the main stems or the trachea altogether. And so usually in kind of the more benign course, 5% to 10% of the time you can't localize at all because they'll have had an episode and it will sustain on its own, and it's a self-limiting process. And unfortunately, sometimes by the time you really try to localize it, the homopsis is significant enough. It's passed its course by the time you really tried to do anything notable.

Really, the goal is being prepared, knowing what you have in your armamentarium, knowing who is available to you and what kind of procedures are available, what specialists are there that can support you, and having a designated team and an algorithm to follow, right? If there are specialists that are available to you that can do things from an IR standpoint and you don't have surgical interventions available to you, then you need to know that up front and vice versa, right? If you have kind of advanced pulmonology team, good intensivists, good interventional pulmonologists, then being able to call them up front to help localize your lesion and perhaps do something endobronchial is really important. You may or may not have all of these resources or very few of them, and knowing who you have up front and what you're... system is capable of is extremely important. And not just the system, but the tools that are available, right? Not every bronchoscopist has every tool, every balloon, every bronchoscope available to them as well. And so knowing beyond just who's there, but what they have is quite important as well. And as always, don't panic, right? With everything, I understand everyone here kind of has a pulmonary or critical care background. That's kind of rule 101 for everything, right? If you can clear your mind, know your algorithm, know your background, and know your steps, it's a lot easier than just seeing the blood in front of you and, you know, losing sight of the basic steps that you need to take to protect this patient.

So initial approach, you see hemoptysis that is massive at this point, right? If you have any sense of what side is the bleeding side, you put that side down, right? And the goal in doing so is protecting the uninvolved lung. For example, if you have a bleeding left lung and you lay the patient on the right side, now all of that hemorrhage can fall into the right side, and that is a recipe for disaster and really quick asphyxiation. And so always protecting the good side is paramount because, as we know, people can ventilate well and oxygenate quite well with one lung, but they can't do it with zero lungs.

As far as airway protection is concerned, like I said, I think having a good sense up front of kind of the prototype patient you have in front of you is this someone that has comorbidities, has a high rate of hemophysis, is coughing frequently but cannot protect their airway. Those are the people that really need airway protection early. And so that's kind of the standard where you get them to your ICU, you intubate them, and then once they're stabilized and their airway is protected, that's when you take those next steps, right? There's no point in rushing someone to a CT scanner while they're asphyxiating. It's important to know your algorithm and stepwise approach. Blind retestation is quite important, right?

having the ability to manage these patients, you need kind of standard hemodynamic support. And whether that be, you know, you guys all know kind of your bleeding algorithms, having large IVs, having significant access, having both fluids, pressors, whatever you need on board, because whatever you're going to do is probably going to require some level of sedation, intervention, et cetera. And if you don't have a preload, in effect, you're already behind the eight ball. Getting into the ICU, as we talked about, having a large endotracheal tube. This is kind of a...

a common problem that comes up because really the rush is always to get a tube in, which is, of course, really important. But if you can anticipate and prepare and be ready for these cases, you know that having an 8.0 or an 8.5 endotracheal tube is much more meaningful than having a 6.5 or a 7.0. And if it's just a matter of taking an extra two seconds to grab that tube, then it really means miles moving forward, right? So when we think about doing a bronchoscopy on a patient in general, we try to have at least two millimeters of room in the endotracheal tube so a patient can ventilate while you're doing therapeutic kind of procedures with your bronchoscope. So, for example, a therapeutic bronchoscope.

is about 6.2 millimeters in outer diameter. Relative to that, if you put, let's say, a 6.5 or a 7.0 endotracheal tube in, you're going to be in one of two situations. You're going to be trying to jam a therapeutic bronchoscope into that space, either get it stuck or not be able to ventilate the patient. Or inversely, you're going to be forced to put a small bronchoscope into that space, which can be done more safely, but then you kind of lose your suction power with a smaller bronchoscope, visualization power, and ability to do as much therapeutics as you'd really like to. So if you are able to anticipate and have available to you a larger endotracheal tube for intubation, it is much more meaningful.

As we kind of mentioned briefly, a multidisciplinary approach is key, right? Having all the right players is really important. Knowing that your ICU team is on board, you have a bed available to them. Having your interventional radiologists, your surgeons, you know, cardiothoracic, thoracic, general surgery, whoever that may be in your institution. Your radiologists that are really good at helping kind of identify the lesion, identifying whatever kind of blood supply is problematic is really important. Having a good collegial approach with your anesthesia team that obviously manages airways much more than we do and really can help guide you and support you in that intubation and those first steps, right? So we talk about this physician patient.

So if you can get an 80 endotracheal tube in, it'll really help with kind of your suction power and clearance. As much as it's problematic as kind of frank blood, what is also problematic is kind of blood clots. And so in these situations, if you find a bunch of blood clots, unless that blood clot is kind of occluding an active bleed, sometimes it's important to clean them because those blood clots are going to occlude airways. So you obviously don't want to unplug something that's been plugged that's actively been hemorrhaging. But if there are free blood clots, it's also important to kind of get those removed.

So once you intubate the patient, able to clear the airways of blood clots and active blood that's kind of obstructing your view, what you'd like to do, if possible, is selectively intubate the good side, right? In doing so, you can actually use your bronchoscope as a guide. Sometimes it's hard to selectively intubate just kind of blindly based on the airway dynamics, and you can use your bronchoscope almost as a guide wire approach to pass the endotracheal tube over it. Other things that you think about, right, that has come up very often is you use a dual-lumen tube to use bronchoblockers to use balloon tamponade. Double lumen tubes, in theory, are good, but in practice tend to be rather challenging for many reasons. One, they're difficult to insert, and even anesthesiologists will tell you it's quite challenging to get in there confidently, consistently, particularly with the rapidity and kind of the success that is needed on a first pass in these situations. Even when in this place, you know, it's an uncomfortable thing for patients. They'll very often need to be paralyzed. And thereafter, you have to ask yourself the same questions, right? What is my next step after the patient's intubated? If your steps are to bronc the patient, your lumen caliber is much smaller than double lumen endotracheal tubes because you effectively need two tubes to be down there at the same time.

And so to fit in the trachea, let's say that's 16 millimeters in diameter, you're not going to be able to get, you know, two endotracheal tubes that are 8.5 millimeters in inner diameter each, right? You're going to have to offer much smaller lumen per tube. So it doesn't really allow the passage of a good-sized bronchoscope. So it's something to think about. So unless it is really your only option, you know, you don't have endobronchial blockers, you don't have large tubes, you don't have bronchoscopes, et cetera, perhaps it's not a good first approach.

And this is kind of just like a visual representation, right? It'd be a lot easier if you can to, looking at the image on the left, selectively intubate the healthy airway and just block off that bleeding that's coming from the unhealthy airway rather than putting a double lumen endotracheal tube in that kind of gives you a little bit less leeway to work with. So once you get to that point and you're able to pass a bronchoscope in, right, what are your goals? Goal number one is to establish laterality. Goal number two is if you can establish laterality, can you establish a lower segment? The reason for this is because the more refined your approach becomes, the easier it is one for an interventional radiologist or other proceduralist who has the opportunity to embolize a lesion, right? If you know that you're bleeding from a left lower lobe, that's very different than just saying it's coming from the left lung, right? To completely embolize all of the vasculature going into that left lung is quite problematic.

Quite similarly, it's an issue with endobronchial blockers. We'll talk about the technique of using an endobronchial blocker, but if you can block part of the airway that's bleeding and you can identify it to a subsegmental level that is more meaningful than having to block off an entire side of the lung, right? So if you can only identify that the left lung is bleeding and you can't refine it more than that, then effectively to protect the right lung, you're going to have to completely block off the left main stem bronchus in order to confidently say you're protecting the right lung. However, if you are able to identify that it's, you know, the lateral segment of the left lower lobe, and you can include either the lateral segment or, let's say, the left lower lobe altogether, then you can get to a point where you can still ventilate the lingula in the left upper lobe. And so being able to refine that approach to localization is quite helpful for overall ventilation strategy.

Detecting endobronchial disease is quite important as well. So if you're able to find something like a large tumor, pedunculated mass, whatever the case may be, then you may be able to intervene upon it yourself, right? Sometimes if you have this fungi and cavitary lesion, then it's hard to do anything endobronchial besides block. But again, if you have like a tumor, then you have tools that are available to you, doing things like laser and APC in order to kind of burn that lesion and prohibit further bleeding, and even do things like cryotherapy, which can be meaningful both from a debulking standpoint, but also from a clot extraction standpoint. So again, the more you can identify, the better you are in kind of supporting the patient.

but also supporting your colleagues who are probably going to take over afterwards. More often than not, bronchoscopy is an intermediary, but not a final step in these diseases. And so it's important to be able to kind of help the patient, help yourself, and help whoever else is going to be engaged thereafter. So these are kind of some more obvious examples, right, of localization. And when you see things like this, you're able to address that a little bit more quickly. And you're kind of seeing here on the left side that someone has inserted a balloon in the right main stem bronchus because, unfortunately, it seems like there's a lot of disease, and it's hard to localize it beyond that right lung. So it's better to kind of protect the left lung altogether and include that right main stem bronchus.

These cases tend to be visually a little bit more challenging, right? If you get a CT scan like this, there's kind of evidence of aspiration on both sides, and maybe there's blood there, maybe there's some bronchiectasis on both sides, and so you have to be a little bit more refined about your approach. Now, we've mentioned balloon tamponade. I apologize for the spelling error on tamponade there, but this is really important, right? And there's, you know, a multitude of balloons that are available to you. Some are long, some are just circumferential. You can use a Foley balloon, a CRE, a Fogarty, whatever the case may be. Having knowledge of your expectation of what you're going to include is pretty important in knowing what size balloon you're going to bring with you, right? Most commonly, something like an 8 French is used, but if you're going to anticipate blocking off like a more subsegmental region, you might need to bring like a 6 or 7 French, depending on the airway. And so anticipating that as well and having multiple tools in your armamentarium is important.

These can be placed and guided in various ways. Sometimes you can just kind of advance a balloon forward and use your bronchoscope to follow it and try to pass it to that area. There, of course, are things like the ARN bronchial blocker that have been created and formulated in order to help anticipate that guidance a little bit more strategically. So I'll kind of go forward and then come back a little bit just so you have a sense of what this looks like. For any of you who haven't used this bronchial blocker system, it's actually quite useful in helping guiding your balloon directly to the site of interest.

So what you have is kind of three connection ports. You have one where your balloon blocker goes through. I hope everyone can see. I don't know if you can see the mouse here. Your balloon blocker can go through here. Two is the site where your bronchoscope can go through, and three is your ventilation port where you connect to your ventilator altogether. Before placing this in the patient or through the endotracheal tube, what you're going to do is you're going to pass the blocker and the bronchoscope kind of through it, and you'll see here. There's a little loop that is at the end of your balloon blocker, and you loop that around the bronchoscope, and there's a little pulling system that you see at the top left here.

And when you pull it, what it'll do is it'll kind of take that loop and tighten it around the bronchoscope so they're hugging one another. Once they're hugging one another, you can drive that bronchoscope and the endobronchial, the blocker itself will kind of follow it. And so you set up this apparatus outside of the patient and then you connect this port right here onto the endotracheal tube. So now these are kind of guided into the airway. Use your bronchoscope to guide the balloon to the area of interest. Then you relax this loop off of the bronchoscope and you advance the balloon into the area of interest and you inflate the balloon.

We want to make sure when you inflate the balloon that you're actually ensuring occlusion, it's not slipping out. So we don't just kind of put it into an airway and inflate it and call it a day, right? What you want to make sure is there's some tautness when you pull back and doesn't easily slip back. And you want to make sure it's in the area of interest, not including airways that you don't need to include, but engaging in whatever area or region that you need most involved. This then kind of, you can measure, there's the length here, and I'll pull back a little bit. These are somewhere between 65 and 78 centimeter catheters, depending on the front you're using, and you have little demarcations of centimeters at the top of the balloon. And so once you pass that balloon and fix it in the spot, you tighten the catheter, you can even tape the catheter into position, and you need to confirm that you know exactly what measurement the catheter has been advanced to. So, for example, if you advance it into a space in the airway and it's at 55 centimeters, and you come back the next day, and it seems to be only at 40 centimeters, it is probably dislodged from the airway and come back more proximally, and that's...

kind of an alarm signal, right, because you might be including an airway more proximally and not protecting the area that you want to protect. And so having a really good sense of where the catheter is quite important. We've also found that these kind of bronchial blockers can sometimes deflate a little bit as well. And so appreciably, if you have the ability and capacity to do so, like radiography intermittently, maybe looking down at the bronchoscope and ensuring that the balloon remains inflated and feeling that cuff component is quite important as well. Like anything else, right, ideally a bigger endotracheal tube. If you can use it, the better. Something like 8 millimeters above will give you access because you are passing both the bronchoscope and the endobronchial blocker through it. And so if you have, you know, like a 6.5 millimeter endotracheal tube, you will not be able to pass them through together. And this is kind of what it looks like when it's passed in the airway, right? So, again, the side port is connected to the ventilator. The top port is connected to the bronchoscope. This port over here is connected to the bronchial blocker. They all kind of connect in tandem into your endotracheal tube and are passed into the area of interest.

Once you do so, you kind of loosen this loop right here and you advance the endobronchial into the area. So here it's the left main stem bronchus. You inflate it and then you confirm both with tactile feedback and as well visual feedback to confirm that's kind of lodged in the appropriate position. It's not loose and it has kind of enough inflation to protect the airway, but it's not kind of hyperinflated and problematic to damage the mucosa. And visually this is what it looks like. So you should be able to kind of see that your balloon is there. It's well taut and spaced in that region. It's not flopping back.

And this is the more proximal part of that balloon. So you see this is kind of a little cuff here, not unlike your endotracheal tube cuff. So you should be able to feel that inflated component to it as well. And if it feels completely clad, that should raise an alarm signal that maybe it's deflated or moved out of that space that you wanted in. All right, so we talked about the blocker. You know, old school bronchoscopy, there's a lot of things that you can do for bleeding besides just putting blockers in, right? So cold tailing levages. I am surprised how well this works in real life, right, when I was kind of a young pulmonology fellow.

I always thought it was silly when someone had like a significant amount of bleeding and I just saw an attending kind of spray cold saline. It really works. And honestly, the vast majority of hemophysis I've seen or, you know, at least any airway bleeding that I've seen, like cold saline can really make a meaningful difference in slowing down significant bleeds. And so you can continue to instill kind of high saline in 50cc alcalots as you need and try to slow down that bleeding if you're able to. Epinephrine tends to be more useful in kind of a focal bleed, like if you just did a biopsy and you're able to see bleed at that site, or there's kind of an endobronchial lesion and you're able to see an area of that endobronchial lesion that's bleeding. Usually when you have kind of massive hemopsis and you're not able to localize actively a spot that's bleeding, epinephrine is not quite as effective. Usually 1 in 20,000 is the dose that's most commonly suggested in this setting. Vasopressin is useful. I've seen an increasing use of tranexamic acid. It is dosed if you are giving it. It can be a talcical or a nebulized formulation. It's usually 500 milligrams. I believe it can be instilled.

three times a day for up to five days. It's quite useful, and we'll go through the mechanism in a little bit, but I found that topical transexamic acid in a setting where you can localize the bleed or the region of bleeding, or inversely, if you have kind of more diffuse bleeding, using a nebulized transexamic acid is quite useful. There's also fibrinogen, thrombin, topical, or systemic that can be helpful in specific instances, and then having endobronchial approaches, right? So if you have lasery, electrocautery, APC, these are all kind of... hot systems that can kind of cauterize the region if you were able to localize one. Inversely, if you need any kind of debulking, freezing, clot extraction, cryotherapy is quite useful. For those of you that haven't seen cryotherapy, it's predicated on the idea that you can kind of freeze cells or kind of freeze a fluid. So it's not useful if you don't have a water density that's available in that tissue. So, for example, if someone aspirates a key or something like that or a coin, there is no water density in that key or coin. So you're not going to be able to really effectively cryo extract it.

However, if someone has a blood clot, there is a lot of fluid and water density to that blood clot, so you'll be able to kind of freeze and extract that more meaningfully. So what's next, right? So we talk a lot about bronchoscopy, but realistically, that is the starting point and very often not the ending point. The goal of a bronchoscopist often is to localize and protect the airway as much as one can, but realistically, conservative management alone still has a high mortality rate because you have not intervened upon the active bleed, right? So very often until recently, surgery was kind of the standard of choice with hemopsis, but it really had high morbidity and mortality associated with it, particularly in emergent situations. And that's why you'll find more and more often, very rarely, that becomes kind of the option of choice if you have multiple options available to you.

And really what's becoming a more minimally invasive standard is bronchial artery embolization. It's considered to be effective, meaningful, and a high success rate overall. So we'll go through kind of some of these in a little bit more detail. So tranexamic acid, right? So tranexamic acid goes through the plasmitogen cascade, and it effectively inhibits the breakdown of clot product, right? So there's multiple pathways for fibrinolysis and plasma activation. And what tranexamic acid does is inhibit those pathways at early stages, and so clot is not effectively broken down. So it helps to have kind of...

not clot formation, but rather clot maintenance in that setting. And there are studies to support this, right? So you'll see like a few studies that are quoted here, and I'll show you in more detail. But, for example, in these studies, they focus more on submassive hemoptysis and their prospective or randomized trials. And you'll see here, for example, patients who randomized to nebulized TXA versus placebo, the TXA group is more likely to have resolution hemoptysis, less likely to need interventional bronchoscopy or bronchial arterial embolization just by use of tranexamic acid. Now, again, these are, technically speaking, submassive hemoptysis cases, not massive hemoptysis cases. They tend to be a bit more complex in those settings, but they do provide some meaningful value.

And this is kind of the details of that study, right? So they admitted 55 patients with hemoptysis. Initially, 50 were screened, 47 of whom were randomized, 25 to tranexamic acid, and 22 to placebo. TXA was given both here in massive and submassive hemoptysis. And you'll see here on the y-axis, the percent of patients that stopped bleeding. You'll see that in the placebo group, 50% of the patients stopped bleeding. And in the tranexamic acid group, much closer to 100% stopped bleeding. And then the mean expectorated blood volume here, you'll see much less in kind of the TXA group versus the placebo group.

Similarly, for a set of patients requiring procedures, the length of stay, it is all meaningfully and clinically significant in the TXA group. So we do know that it certainly has its clinical utility in hemophysis. And then I can kind of give you more and more data, but, you know, likelihood of recurrent hemophysis goes down, likelihood of death goes down. So it is an important adjunct that you have available to you. And oftentimes when I am called to a hemophysis case, like if the medical ICU calls me in the middle of the night saying we have a hemophysis case, not only am I preparing my bronchoscopy set, but I actually do ask the team to order transexamic acid or a thrombin up front. And so those kind of can be like I'll very often administer thrombin topically and have TXA ordered and available to us.

So CTHS, this often is, I think, can be paramount, but tends to be challenging in a clinical setting where there's a lot of panic and a lot of kind of critical illness, right? You guys know that getting a patient down to a CT scanner in these instances is not an easy thing to do. However, it can both be meaningful diagnostically, but also paramount in knowing where a disease is and being able to intervene upon early. Very often in my pulmonary critical care fellowship, if a patient was coming to the emergency department, we knew they already had access and were intubated. and they were coming up to the medical ICU, we would say, hit the CT scanner on your way up, right? We know CT scanners' technology has evolved massively over the last few decades, and you can get a CT scan done on an order of seconds to minutes at most.

And if you can use a CT angiogram to really identify the area of bleeding, one, it gives you a quick route to go through via your bronchoscopy. You know where you're going and you can get at it quicker. And you can already kind of recruit your interventional proceduralist in a much more hasty fashion because they already, when they're kind of opening up their suite, they already know where they're going, right? If you do not have a CT angiogram available to you and you get them down to interventional radiology, they're going to be starting to shoot angiograms top, right, left, down, more contrast used, more time spent perhaps trying to localize the lesion versus if you already have a CTA done in route to the medical ICU. By the time your colleagues are available and the suite is open, they already know that they're going, for example, to the right lower lobe or the right middle lobe. So it's very useful in localizing the bleed, having your kind of interventional colleagues available and ready to go, identifying possible systemic collaterals because that is also a meaningful thing, right? Very often you'll embolize a lesion, and then you'll notice that they'll start bleeding a few days later because there have been collaterals that have been formed to that lesion, and so it might re-bleed if those are not addressed. And so knowing if there are systemic collaterals on the CT angiogram can also guide embolization to those sites. So once they get to that point, right, you hope that you have –

these procedures available to you, IR is generally amazing at doing these things and making themselves available, right? And so what they'll do is once they have the suite available, they'll do some form of arteriography and embolization. And like I said, if you already have localization available to you, and both from a bronchial approach, but also from a CT approach, then they can kind of guide their catheter to the site of interest and get it going. Most often, there's a bronchial artery that needs to be addressed. We do know that there are risks associated with it, right? When they embolize these, the vasculature, there is a non-zero risk of transverse myelitis causing paraplegia.

Generally speaking, of course, when we're in these instances, we feel strongly that the benefit outweighs the risk by quite a good amount. But that being said, we do understand that that risk does exist. Overall, they define a success rate of about 85%. So although it is highly successful, some of these patients still do re-bleed. The re-bleeding can be from kind of a progression of a malignancy or progression of an infection. It could be from collaterals that have escaped the embolization process. And a few times, you will have to send them back to interventional radiology and they'll get embolized again. So that is something to think about.

Based on the statistics that we have, like I said, although immediate hemostasis is controlled the vast majority of the time in treated patients, recurrence can happen. I think we tend to see it somewhere around 25% of the time, but as with most studies, right, there are wide variations, and so you can see literature that gives you somewhere between 10% and 55% of the time. I think most intensivists will tell you that 55% is a bit of a stretch, and we don't tend to see that. They tend to be very good in terms of control overall. And so this is kind of more evidence that supports it, but also tells us that there are certain disease processes.

like those patients who have active infections, fungal pneumonias, et cetera, that tends to be worse, right? So I'll kind of point you to this third spot here that says immediate cessation of hemopsis was achieved in 86%. Hemopsis was controlled in 72% and recurred in about 28%. And 11% or 22% required repeat embolization, which, like I kind of mentioned, I think we would generally quote somewhere around 25%. But here you'll see that the worst outcomes were observed in patients with aspergilloma. All six patients in this study suffered recurrent bleeding, and three were 50% died from massive hemopsis. Aspergilloma was also associated with increased risk of hemopsis recurrence, right?

So we'll often see that kind of these diseases, either because they involve multiple collaterals, infection has spread, involves kind of a cavitation, et cetera. In those instances, there are higher likelihood of re-bleeding. This is the kind of points that we talked about, right? Being thoughtful about recannulization, incomplete treatment, recruitment of collaterals, those are all higher likelihood risk factors of re-bleeding, but patients can be retreated, right? Re-embolization is possible. Just because someone got embolized once doesn't mean they can't necessarily get embolized again. And so keeping your multidisciplinary teams engaged in these processes, even after embolization happens, is really paramount to consistent and continued success rather than just initial and individual success. Surgery is ultimately kind of...

the final frontier in many ways in massive hemopsis, right? So the goal, of course, is to have localized bleed preoperatively because realistically speaking, otherwise they're not just going to do kind of a full pneumonectomy, right? If you can remove a lobe, for example, if someone has a large infection, then that is much easier to do than ask them to do something much larger. So ideally you want to be at a point where you've localized the bleeding, isolated, and secured the airway, right? And being thoughtful to the fact that patients need to have lung reserve to survive these things. There's no point in someone with a diffusion capacity of, you know, 20% and FEV1 of...

you know, 0.78 liters to go through this large surgical recession, just not be able to survive the perioperative and postoperative situation. And so knowing your patient profile is also really important to this end. There's a high risk of operative bleeding, asphyxia, BPF, and all of these things. And so... Surgeons are very thoughtful about what patients are likely to succeed and kind of overcome these high morbidity and high mortality situations. And so candidacies are quite important to consider and the likelihood of success in not dying in the intraoperative setting. It is the procedure of choice for certain situations that are very unlikely to be managed nonoperatively, things like massive chest trauma, large kind of aspergillomas that are re-bleeding and taking over a large part of the lung. Iatrogenic vasculature ruptures, things like right heart cathode cause pulmonary artery ruptures, very difficult to control by alternative means.

And, you know, hemopsis does refractory to other interventions. Another cause of hemopsis that we see is the post-tracheostomy bleed, right? So usually if you're going to see bleeding that is kind of localized and regional, it tends to be in the first few days post-tracheostomy. The kind of the terrifying bleeds that we see that are associated with tracheonominate fistulas are usually on the order of several weeks post-tracheostomy. And then if you're getting bleeds on the order of months afterwards, that generally tends to be something like inflammation, irritation of granulation tissue, irritation of the airway from the tracheotube itself.

understanding not only the anatomy of the patient, but also the timing of the trache will also help guide what the likelihood is that the patient is bleeding from a certain situation. So if you end up tracheing the patient and they're having some minor oozing around the tracheostomy on day one post-procedurally, right? Very often you have to ask yourself, does this patient have a coagulopathy? Are they on blood thinners? Do they have any submucosal vessels? Very often we're ultrasounding these patients pre-tracheostomy. We'll see a lot of kind of small venous collaterals in the area, and certainly one might erode, and it just requires a little bit of topical treatment, gauze packing, silver nitrate sticks, et cetera.

There are kind of bigger vascular beds that exist, and you have to be aware of those either when having CTs beforehand, ultrasounding, et cetera. And so if you injure, you know, a thyroid artery, the thyroid isthmus is quite bloody when it's injured. And suction trauma, those are things to think about and might take a little bit more work to eradicate. The fear complication rate is the tracheoanominate fistula. Usually the highest risk that we think about is if someone has a high-riding anominate artery. You know, when we do these tracheostomies, we try to do the tracheostomy between the first and second tracheal ring or the second and third tracheal ring. One of the reasons for that is because you really start getting into problems abutting the tracheoanominate artery once you drop towards the area of the fourth tracheal ring. And so if you happen to trache around between the third and fourth tracheal ring or the fourth and fifth, then the likelihood goes way up that your low-lying tracheostomy can really erode into the tracheoanominate artery.

Similarly, if you don't kind of assess your vasculature beforehand, once in a while we see patients who have those arteries that are much more high riding towards the first and second tracheal ring, and the likelihood of that invading into that space goes up as well. Usually that takes weeks, so we'll see if you're going to see a tracheal nominate bleed. That is generally around a month post-procedure, and so if you hear a story of someone having bright-lead blood coming straight out of their trache tube about a month after, I would really have your alarm bells on. And, you know, people always ask, you know, what's the thing to do in these situations, right? And so your tracheoanominal artery is usually kind of coming horizontally across the neck, usually inferior to where your tracheoanominal artery is. So if you think someone's having a huge bleed through there, one of the easiest things to do until you're able to kind of get your resources available too quickly is actually kind of advance your digit in front of the tracheostomy site, underneath the skin, and kind of hook forward, which will pinch off the tracheoanominal artery. And so, you know, if you need to bite minutes when someone's actively hemorrhaging and you think that's really the cause,

That's the quickest way to occlude it and really get people to kind of surgical management. So we'll go through a case example, right? So this is a 63-year-old male with a history of squamous cell cancer in the right upper extremity. It was amputated eight months ago. He was recently found to have metastatic disease. He presented outside hospital with, quote, massive homopsis and was intubated for airway protection and transport to your institution for further evaluation and management. So you take a look here, and it seems to raise a question of whether there's some kind of cavitating lesion, right? It's hard to completely see here.

But it looks like to some degree there's some kind of circumferential disease process, maybe some hair in here, who knows, maybe necrotic lesion, fungus ball. It's hard to say definitively, but clearly this is an area of interest, right? So what are your next steps, right? We kind of went through this. If you're concerned that this is massive homopsis, patient cannot protect their airway. They're quite ill. You know, you make sure you stabilize the patient. You have access to chemodynamic management. You intubate for airway protection. You call your resources that are available to you. Make sure you're a bronchoscopist, your intensivist, your interventional radiologist. If you're worried this is malignancy, perhaps radiation oncology as well, see what imaging is available to you from a safety standpoint. Can you get this patient to a CT scan?

Are they so far beyond that you go directly to something like comfort measures? So thinking about that early is really important, right? And so you go through the algorithm, you do a bronchoscopy, you don't see anything actively bleeding, but you kind of see perhaps a lesion right there. that obviously doesn't look like it's hemorrhaging, right? So you see no evidence of continued bleeding. You biopsy the suspicious vision, and then what do you recommend? You send them to IR, you send them to radiation oncology, you send them to thoracic surgery. Generally speaking, I think most people, given the concern of massive hemopsis, would call IR pretty early to do something like a bronchial artery embolization, right? Generally, as we talked about, there's good short-term success, but about where the patients have recurrence, and there is a 1 to 6% of transverse myelitis that can cause paraplegia.

So when someone goes to embolize these patients and they don't see kind of active blanching, which means like, you know, contrast extravasation out of it, which would suggest active hemorrhage, sometimes what they see is tortuous vessels or ectasia of the vessels that suggest that that's a culprit lesion. And so if those are high-risk lesions, what they'll do is they'll embolize it even when they don't see contrast extravasating, right? So this patient, you know, they just saw some tortuous vessels. They didn't see any major ectasia, any active hemorrhage. Radiation oncology is consulted. Patient doesn't really need therapy because they're not bleeding anymore. They're not coughing up blood.

Everyone feels good about it, pats themselves on the back. They said we did the right thing. We followed the algorithm, and it went on. Two weeks later, the patient has recurrent massive homopsis. By the time they get into the hospital, they have a PA arrest, they're intubated, they get a bronchoscopy, there's still that right lower local region that's identified as perhaps a source of homopsis, and so at this point, a bronchoblocker is placed. And so you ask yourself, we kind of went through this, right, but what is the next step? IR, radiation, surgery, do you want further imaging? Seems like this patient was pretty stable this time around, and so they did have an opportunity to get a CT angiogram. And what they found was that lesion of concern that they first identified was not a cavitary lesion, but rather a large pulmonary artery studio aneurysm, right?

And so if you take a look here, you'll see that there's a ton of contrast that's extravagant, not extravagant, excuse me, but filling that space that is kind of easy to identify if you have the opportunity to do a CTA, right? So this is kind of missed on the first go around because the patient didn't have the opportunity to go to a CT scanner and kind of jump to the ICU. Ideally, if this patient had this CT angiogram early, they would have had the opportunity to actually identify this lesion. And so they go into IR. Hopefully these things will play. They do not, unfortunately. I apologize. But what you'll have seen is kind of contrast filling into that space, and you're able to really localize the pseudoaneurysm, right?

And so that pseudoaneurysm was managed successfully. But unfortunately, the patient never really was able to recover their mental status. Ideally, right, if you had the ability, the time, and the stability to get a CTA up front, perhaps this could have been managed on the first go around. But oftentimes, time and clinical status doesn't allow. But again, knowing your algorithm and knowing that not what you're doing alone is important, but rather what your procedure is and what your management is in order to guide the next five, six, seven steps can kind of guide appropriate management in a meaningful way.

So to summarize, really step number one is stabilize your patients and have airway control, right? If you don't have airway control, if the hemopsis isn't kind of stabilized in some way, if you don't have hemodynamic stability, it's difficult to take steps three, four, and five. If you know what side the patient's bleeding, turn that side down. Protect the healthy lung at all costs because that's pretty much the only thing keeping that patient alive. Very often you'll see a patient in the ICU, the bleeding side is localized, and they're still kind of laying on their back because that's the standard, right? And so make sure that you don't overlook that.

Localizing the bleeding from side and subsegment, if you can do so, is really important. If you have the time to get, you know, three-dimensional cross-sectional imaging, it provides a wealth of information and really helps to standardize everyone's approach and take meaningful steps in a quick way. Blood products, volume resuscitation, having your resources, your bronchoscopes, your interventional radiologists, your surgeons, all of that, your intensivists, you know, your ICU nurses, all of that. People have become very good at working in multidisciplinary approaches because I think everyone knows that. Multiple tools is always better than one tool, and multiple minds is always better than one mind. And so really getting your resources, getting your mind together, getting your strengths together cannot go underappreciated in such a setting. I'm not sure if I thanked up front Christine Argento, Ed Tickering, and Samira Shigayi for putting these slides together, so I want to just make sure I thanked them. And, you know, rule number one, right, in anything in critical care, don't panic, right? Trust in your knowledge of your disease, trust in your knowledge of your management, trust in your support staff, and trust in kind of your specialists to help guide you through it.

Beyond Hope Project with Jason Tharp Beyond Hope Project Welcome to 'Beyond Hope Project,' a beacon of inspiration in the podcast world. Join Jason Tharp as we embark on a transformative journey, exploring stories that awaken the will to start anew and find the strength to rise from setbacks. 'Beyond Hope Project' is about lighting the way to your starting line, not dictating your path. We delve into narratives that foster optimism and belief in a future where dreams become achievements. Each episode is a tapestry of positivity, enthusiasm, and comforting support, resonating with the essence of hope. This podcast goes beyond storytelling; it's a movement of positive change rooted in authenticity and transparency. We provide real tools for real journeys, infusing more hope and joy into the world. 'Beyond Hope Project' stands as a testament to the transformative power of hope and the limitless potential of the human spirit. Join us in transcending boundaries and breaking barriers. Here, we prove dai Veteran Chat Project Kyle Turner Our goal is to reach as many Veterans as we can. We noticed a lot of the podcast personalities tend to be unrelatable to the every day joe. Not taking anything away from anyone just hoping to give more people a place to feel connected to something. KZ and Kyle are Army vets who deployed together for OIF 07-09 and OND. Now close to 15 years later we are finding a way to open up about our issues, and find a way to build a community. Paramedic Philanthropy Project Melissa Ade Podcast by Melissa Ade Bigfoot Information Project Podcast Bigfoot Information Project Occasional conversations with leading researchers and investigators regarding the animal commonly referred to as bigfoot.

Frequently asked questions

How long is this episode of Maryland CC Project?

This episode is 54 minutes long.

When was this Maryland CC Project episode published?

This episode was published on January 9, 2023.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Maryland CC Project episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.